In an article e-published on March 12 ahead of print in Lancet Oncology, Zinzani et al. from the University of Bologna (Italy) expanded on previously published results (Cancer. 2008;112: 856-862) of a prospective, open-label, nonrandomized phase 2 trial of combined fludarabine and mitoxantrone chemotherapy plus ^sup 90^Y-ibritumomab tiuxetan radioimmunotherapy (RTT) in patients with untreated nonfollicular non-Hodgkin's lymphoma (NHL).
Pages to are hidden for
"RIT and NHL"Please download to view full document